Tretinoin - Valeant

Drug Profile

Tretinoin - Valeant

Alternative Names: All-trans retinoic acid; RAM 0.08%; Renova; Retin-A Micro; Retinova; Tretinoin - Ortho-McNeil

Latest Information Update: 09 Mar 2016

Price : $50

At a glance

  • Originator Ortho-McNeil
  • Developer Valeant Pharmaceuticals International
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne; Photodamage

Most Recent Events

  • 31 Jan 2014 Registered for Acne in USA (Topical, 0.08% microsphere gel)
  • 30 May 2013 Biomarkers information updated
  • 08 Jul 2010 Efficacy data from a clinical study comparing two treatment regimens in Acne released by Ortho Dermatologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top